Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your post contained a lot of good information about the criticality of marketing and sales experience necessary for successfully marketing a drug. Nonetheless, focus is putting the cart before the horse. KOLs will not get the Blarcamesine approved for the treatment of Alzheimer's. Regulatory approval is the end result of trials that have convincing data that meets established standards for efficacy that exceed any downsides of adverse events. That approval process lies squarely on the shoulders of Missling and AVXL. To date, some limited progress toward regulatory approval has occurred but nothing significant such as the filing of applications for approval. In that regard, the ball remains under center and play has not commenced. Once the ball is moved, partners, key opinion leaders, drug advocates, patient groups, etc. can be brought into the game as additional players.
Bio-Scoping Issues New AVXL Analysis Updates
Bio-Scoping has recently released two "paradigm change" (his words) updates to his analysis of AVXL's Phase 2b/III trial results. He introduces the updated analysis with the following quote: "The More I Look Into Phase 2b/3 The More Efficacy I See". Paradigm Change In Looking into Phase 2b/3 in Alzheimers.pdf is just for background information. Paradigm Change MMSE Histogram is the newest report. If you find merit to the additional new analysis, you may be uplifted regarding the upcoming full data set from the trial and more hopeful about the potential for regulatory approval of Blarcamesine for the treatment of Alzheimer's Disease.
https://www.patreon.com/posts/more-i-look-into-102709490?utm_medium=post_notification_email&utm_campaign=patron_engagement&utm_source=post_link
Another prediction by Georgie that hasn't aged well. Anyone that doesn't live in a shoebox and knows even a little bit about what is going on in the U.S. economy figured out months ago that those predicting Fed rate cuts in early 2024, or beginning no later in June, were blowing smoke out their rear ends. Not only have the three rate cuts gone up in smoke but now it looks like there may be no interest rate cuts at all in 2024. Even though rates should not be cut, it's still a risky bet that they could be because there is a presidential selection process to be arranged in late 2024 and the ice cream guy needs those rate cuts to have a chance of winning.
Anyone that has been to a grocery store in the past year, or brought darn near anything, knows that prices have continued to increase. That is true of just about all consumer costs with the qualification that the rate of inflation has somewhat decreased for certain items. Costs are higher across the board an are no where near the Fed's goal of 2%. Recently the cost of oil and short-term borrowing costs have ramped back up, which will continue to put future pressure on consumer prices. And, of course, the Fed keeps printing money at an out of control pace to finance the ongoing wars. That increased debt of an additional $1 trillion every quarter or so is a huge driver of inflation. Fed chair Powell has now waivered after being slapped with reality. Even economics talking heads are now gushing that the earliest cuts may not start until September with the possibility of no cuts at all in 2024. Bank of America is still forecasting a December 2024 rate cut while out of the other side of the mouth warning that there is a "real risk' that cuts won't appear until March 2025 "at the earliest".
https://www.cnbc.com/2024/04/17/wall-street-pushes-out-rate-cut-expectations-sees-risk-of-no-action-until-2025.html